Category: Pα+ - Page 9 - Psychedelic Alpha

Read more about the article Insights from the European Medicines Agency’s Psychedelics Workshop: A Pα+ Dispatch

Insights from the European Medicines Agency’s Psychedelics Workshop: A Pα+ Dispatch

Post published:April 23, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV Ibogaine

Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV Ibogaine

Post published:April 17, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran Singh

Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran Singh

Post published:April 12, 2024
Post category:Interviews Pα+

Read more about the article MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic Therapies

MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic Therapies

Post published:April 5, 2024
Post category:Analysis Pα+

Read more about the article Pα+ Psychedelic Patent Analysis: February 2024

Pα+ Psychedelic Patent Analysis: February 2024

Post published:March 30, 2024
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #160: Mutual Recognition for MDMA-AT in the UK? Beckley Shares Cut of 5-MeO-DMT Data; and more

Pα+ Psychedelic Bulletin #160: Mutual Recognition for MDMA-AT in the UK? Beckley Shares Cut of 5-MeO-DMT Data; and more

Post published:March 29, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article ICER Draft Evidence Report on Lykos’ MDMA-Assisted Psychotherapy Deems Clinical Evidence “Insufficient”

ICER Draft Evidence Report on Lykos’ MDMA-Assisted Psychotherapy Deems Clinical Evidence “Insufficient”

Post published:March 27, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin

Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin

Post published:March 21, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Fluence’s Elizabeth Nielson on Professional Education for the Psychedelics Field

Fluence’s Elizabeth Nielson on Professional Education for the Psychedelics Field

Post published:March 19, 2024
Post category:Interviews Pα+

Read more about the article Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder

Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder

Post published:March 14, 2024
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.